



RSC Advances

rsc.li/rsc-advances






ISSN 2046-2069



ROYAL SOCIETY
OF CHEMISTRY


 Cite this: *RSC Adv.*, 2022, 12, 32328

Naproxen release from carbon dot coated magnetite nanohybrid as versatile theranostics for HeLa cancer cells†

 Mochamad Z. Fahmi,¹  ^{*,ab} Nurlailatul Machmudah,^a Putri Indrawasih,^a Aswandi Wibrianto,¹  ^{ac} Musbahu A. Ahmad,¹  ^a Satya C. W. Sakti^{ab} and Jia-yaw Chang^c

Nanohybrid magnetite carbon dots (Fe₃O₄@CDs) were successfully synthesized to improve their applicability in multi-response bioimaging. The nanohybrid was prepared *via* pyrolysis and further loaded with naproxen (NAP) to promote drug delivery features. The characterization of the synthesized Fe₃O₄@CDs demonstrated the existence of Fe₃O₄ crystals by matching with JCPDS 75-0033 and its narrow size distribution at 11.30 nm; further, FTIR spectra confirmed the presence of Fe–O groups, C–O stretching, C–H sp², and C–O bending, along with dual-active fluorescence and magnetic responses. The nanohybrids also exhibit particular properties such as a maximum wavelength of 230.5 nm, maximum emission in the 320–420 nm range, and slight superparamagnetic reduction (Fe₃O₄: 0.93620 emu per g; Fe₃O₄@CDs: 0.64784 emu per g). The cytotoxicity assessment of the nanohybrid revealed an excellent half-maximal inhibitory concentration (IC₅₀) of 17 671.5 ± 1742.6 μg mL⁻¹. Then, the incorporation of NAP decreased the cell viability to below 10%. The kinetic release properties of NAP are also confirmed as pH-dependent, and they follow the Korsmeyer–Peppas kinetics model. These results indicated that the proposed Fe₃O₄@CDs can be used as a new model for theranostic treatment.

 Received 8th September 2022
 Accepted 27th October 2022

DOI: 10.1039/d2ra05673a

rsc.li/rsc-advances

Introduction

Inorganic-based nanomaterials including magnetic nanoparticles (MNPs) and carbon dots (CDs) have been increasingly studied owing to their unique optical, electrical, and magnetic properties.³ Magnetite (Fe₃O₄)-based MNPs are particularly interesting due to their superior physical properties including biodegradability, biocompatibility, and superparamagnetism. The material distorts human tissue's local magnetic characteristics to enhance image contrast. Fe₃O₄ has thus gained interest both in the field of magnetic storage and in biomedical areas including biosensor development,⁵ hyperthermia therapy,⁶ drug delivery,⁷ medical imaging,⁸ clinical diagnoses,⁹ cardiovascular therapy,¹⁰ and magnetic separation.¹¹

Several studies reported the application of Fe₃O₄-based MNPs for clinical use as a contrast agent in magnetic resonance

imaging (MRI).^{12,13} The current MRI contrast agents mostly form Gd-based molecules and remain at a high risk of toxicity due to their long-term existence in the human body without systemic degradation. However, Fe₃O₄-based MNPs stand as better alternatives due to their high-level acceptance in the human body (about 20–25 mg), which is similar to the amount of contrast agent injected per person (0.5 mg kg⁻¹). This reason spurs many studies on obtaining MNPs by various methods including hydrothermal, solvothermal, electrochemical, and sonochemical methods and co-precipitation, microemulsion, sol-gel, and thermal decomposition.^{14–20} Among all methods, co-precipitation is a promising method that allows for short preparation time, low-cost precursors, and low-temperature processing.^{21,22} However, colloidal Fe₃O₄-based MNPs tend to agglomerate in water due to high surface energy and magnetic dipole–dipole attraction between crystals.^{3,23} Surface modification can enhance their colloidal water stability, which also influences their biodistribution and bloodstream circulation.²⁴ The proposed methods have been reported to involve modification or coating of the surface of Fe₃O₄ with carboxylates, sulphonates, gold, phosphates, silicon compounds, polymers, and CDs. Thus, the modifications are also responsible to reduce its hydrodynamic size and improve its stability in water.^{13,25,26} It is known from previous studies the carboxylate moiety of citric acid (CA) has been widely used as a stabilizing agent to bind to

^aDepartment of Chemistry, Universitas Airlangga, Surabaya 61115, Indonesia

^bSupra Modification Nano-Micro Engineering Research Group, Universitas Airlangga, Surabaya 60115, Indonesia

^cDepartment of Chemical Engineering, National Taiwan University of Science and Technology, Taipei 10607, Taiwan, ROC. E-mail: m.zakki.fahmi@fst.unair.ac.id; Fax: +62-31-5922427; Tel: +62-31-5922427

 † Electronic supplementary information (ESI) available: UV and PL spectra; photograph images of nanohybrid; turbidity data; CC50 data; kinetic release of naproxen from Fe₃O₄@CDs-NAP nanohybrid with pH variation. See DOI: <https://doi.org/10.1039/d2ra05673a>


the surface of MNPs and increase the negative charge and hydrophilicity.^{22,25,27,28}

However, CDs have also attracted attention as a promising material for numerous applications such as photocatalysis, metal detection, drug delivery, bioimaging, bio-labelling, bio-sensing, and light-emitting diodes or optoelectronic devices due to their photoluminescence (PL).^{29–31} Further, their luminescence offers good cell-imaging qualities including long-term cell tracking, deep-tissue penetration when excited at longer wavelengths, and better resistance against photo-bleaching than fluorescent dyes.^{27,32} The commonly used CDs have been synthesized by top-down and bottom-up approaches including laser ablation, microwave radiation, hydrothermal/solvothermal methods, thermal decomposition, and pyrolysis.^{6,33–36} Focusing on CD synthesis, it was reported that the process could support the nucleation and growth stages of other NPs, leading to new functional materials. Thus, CDs play a critical role in preventing the agglomeration of composite materials.³⁷ CDs synthesized from CA are favourable, which demonstrated the enhancement of magnetic compatibility with solvents, reduced aggregate formation, and increased NP stability; importantly, these water-soluble CDs have shown high PL with a quantum yield (QY) of approximately 42.2–88.6%.^{32,38,39}

Combining CDs and MNPs as hybrid NPs allows multi-purpose nanomaterials in their applications.^{34,40} Several studies have thus investigated nanohybrids comprising MNPs and CDs in diverse fields such as catalysis, sensing, fuel cell technology, optoelectronics, magnetism, energy, and biomedicine.^{37,41} Some efforts have been focused on preparing novel hybrids comprising CDs with inorganic NP cores such as iron oxide, zinc oxide, or silica. Singh *et al.*⁴² have successfully synthesized magnetic quantum dot Fe₃O₄-ZnO nanohybrids that targeted cancer cells. Moreover, BSA-modified hybrid nanoclusters have been synthesized to improve the response during magneto-fluorescence imaging and drug delivery.⁴¹ However, each imaging modality has its advantages and disadvantages. Multi-modal imaging techniques combine each modality's strengths and further improve diagnostic techniques to be developed on reaching the effectiveness of diagnostic protocols.^{43,44} For instance, magnetic resonance imaging (MRI), owing to less sensitivity, could be combined with compassionate modalities like computer tomography (CT). The combination of CDs covering MNPs promotes advantages based no toxicity issue and could be used in drug delivery systems.

In case of delivery systems upon nanocarriers, a study on the releasing character of the drug may be a crucial aspect to support desired therapy technique. Nevertheless, most of the hybrid materials are reported without any details on how they carry drugs to the target site, and are prepared *via* complicated processes along with the costly design. Some studies have reported the combination of CDs and Fe₃O₄ nanohybrids, which exhibit superior and multi-functional features on detecting particular compounds such as doxycycline,⁴⁵ *Geobacter sulfur-reducens*,⁴⁶ bacteria,⁴⁷ and metals.^{47,48} However, integrative studies on the evaluation of naproxen release from the nanohybrid and its potential delivery have not been reported yet. In

present research, we propose simple *in situ* synthesis of a nanohybrid of Fe₃O₄ NPs conjugated with CDs. The nanohybrid further loaded with naproxen (NAP) is used as a non-steroidal anti-inflammatory drug, as it is commonly used as a modifying adjunct during healing.^{49,50} The proposed nanohybrid comprising both Fe₃O₄-based MNPs and CDs and thus incorporating both of their functionalities in a single NP is very promising for multi-response bioimaging such as MRI and CT.

Experimental

Materials

Iron (III) chloride (97%; FeCl₃), ammonium iron (II) sulphate (99.97%; (NH₄)₂Fe(SO₄)₂·6H₂O), ammonium hydroxide (25%; NH₄OH), ethanol (99.5%; C₂H₅OH), Na-NAP (98%), and 4',6-diamidino-2'-phenylindole dihydrochloride (DAPI) were purchased from Sigma-Aldrich, USA. CA (99.5%; C₆H₈O₇) and hydrochloric acid (37%; HCl) were purchased from Merck, Germany. Dulbecco's modified Eagle's cell medium and phosphate buffered saline (PBS) were purchased from GIBCO Thermo Scientific, USA. A molecular weight cut-off (MWCO) membrane (1000 Da) was purchased from Orange Scientificque, Belgium. All chemicals were used directly without further purification.

Synthesis of Fe₃O₄@CA and Fe₃O₄@CDs

Fe₃O₄@CA was prepared following the procedure previously reported in the literature with slight modification.^{51,52} First, 8.1 g of FeCl₃ and 9.8 g of Mohr's salt were dissolved in 25 mL of deionized (DI) water and added to 20 mL of ammonia under vigorous stirring. The mixture was then subjected to ultrasonication for 30 min until the pH reached 9 and then stirred vigorously at 70 °C for 30 min. The resulting black mixture was separated by centrifugation (900 rpm) and washed with DI water and ethanol. The obtained Fe₃O₄ was added to 100 mL of DI water, stirred and ultrasonicated for 30 minutes. Once reaching pH = 5, the mixture was stirred at 80 °C for 1 h to obtain nano-Fe₃O₄.

Next, 15 g L⁻¹ of CA was added to the mixture at a rate of 2 mL min⁻¹ for 30 min. The resulting black mixture was separated by centrifugation (900 rpm) and washed with DI water. The black precipitate of Fe₃O₄@CA NPs was collected and added to more CA (ratio 1 : 1) and furnace at 270 °C for 1 h to obtain the Fe₃O₄@CDs nanohybrid. The colloidal solution was then prepared by dissolving the resulting nanohybrid in 1 M sodium hydroxide (NaOH) and then purifying it on a dialysis membrane (MWCO; 1000 Da) for 2 h.

Preparation of NAP-loaded Fe₃O₄@CDs and drug release assessment

NAP-loaded Fe₃O₄@CDs (Fe₃O₄@CDs-NAP) were prepared by mixing the NAP solution with Fe₃O₄@CDs at a molar ratio of 1 : 10 at room temperature and stirring for 24 h. Fe₃O₄@CDs-NAP were then dialyzed using an MWCO 1000 Da membrane for 24 h to remove impurities. The NAP concentration contained in the Fe₃O₄@CDs-NAP was calculated by matching the maximum



absorbance of NAP with the original standard curve at 330.5 nm.⁵³

Confocal laser scanning investigation

This observation was started by culturing HeLa cells, which were first seeded in a 6-well plate containing a culturing medium (2 mL) and cultured for 24 h. After incubating with the sample (300 μ L) for 60 min, the cells were washed three times with a PBS solution and then fixed with 70% alcohol for 10 min. Fluorescence images of HeLa cells were acquired using a Leica TCS SP2 inverted confocal microscope (Leica Microsystems) equipped with a 63 \times 1.32 NA oil immersion objective. Confocal images were obtained by illuminating the samples with inline Ar (488 nm) and He-Ne (503–680 nm and 588 nm) lasers.

Cytotoxicity evaluation of Fe₃O₄@CDs and drug inhibition assessment

A cytotoxicity assessment was performed using a Cell Counting Kit-8 (CCK-8) from MedChemExpress, New Jersey, USA, in a 96-well plate for HeLa cancer cell lines. The cancer cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) at a density of 250 000 cells per well and incubated for 24 h. Then, the cells were washed with 10 μ L of phosphate and different concentrations of Fe₃O₄@CDs were added. After that, the medium was allowed to equilibrate for 1 h. The contents of each well were then added to 20 μ L of the CCK-8 reagent at 37 $^{\circ}$ C in a humidified 5% CO₂ atmosphere. Finally, the absorbance of each sample at 480 nm was recorded using an enzyme-linked immunosorbent assay (ELISA) reader.

Characterization

The particle size was measured using a dynamic light scattering (DLS) instrument Malvern Zetasizer and an atomic force microscope (AFM). Then, the diameter size distribution was obtained using the ImageJ software. The functional groups of the NPs were studied using a Shimadzu IR-Tracer-100 Fourier-transform infrared spectrometer (FTIR). X-ray powder diffraction (XRD) patterns were acquired using a Phillips X-ray diffractometer with a Cu-K α line ($\lambda = 1.54 \text{ \AA}$). Ultraviolet-visible spectrophotometry (UV-vis) absorption spectra were recorded using a Shimadzu 1800 UV-vis spectrophotometer. PL spectra were recorded using a FluoroMax-4 PL spectrophotometer equipped with a xenon lamp. The QY of Fe₃O₄@CDs was compared with that of Rhodamine 6G (R6G, QY = 95%) and calculated as follows:⁵⁴


$$QY = QY_r (I_s/I_r) (A_r/A_s) (\eta_s/\eta_r)^2 \quad (1)$$

where I , A , and η correspond to the PL intensity, UV absorbance, and refractive index, respectively. Subscripts r and s represent the Fe₃O₄@CDs and R6G markers, respectively. The magnetic properties of the NPs were measured at room temperature using a vibrating-sample magnetometer (VSM) with a maximum applied field of 8 kG.

Results and discussion

Synthesis and characterization of the nanohybrid


For preparing magnetite nanoparticles, we first prepared bulk magnetite (Fe₃O₄) by mixing the ionic iron sources by a co-precipitation method following reaction eqn (2):



The obtained magnetite further was introduced to CA to cover the magnetite and enhance its stability. As shown in Scheme 1, the carboxylate moieties of CA stabilize the magnetite *via* temporary complex formation and the rest of carboxylates promote Fe₃O₄ for further reaction.⁵⁵ The interaction between CA and magnetite was mediated *via* electrostatic interaction from the carboxylate moieties of CA close to the iron part of magnetite. This design not only covers magnetite itself, but also stabilizes the particle. The CA to iron interaction may rob the iron oxide particle, resulting in a lower diameter of magnetite after introducing CA (next on size-diameter discussion). This CA-coated magnetite was further treated *via* pyrolysis after the addition of excess CA. The pyrolysis process allows carbonation of CA in between. In this process, any hydroxy moieties on CA can interact with hydrogen or other hydroxy species, covering magnetite and obtaining a carbon-like structure of carbon dots covering magnetite (Fe₃O₄@CDs) as a new layer, as detailed in Scheme 1. The produced nanomaterial was studied by several characterizations. The carbon precursor on the outer layer of Fe₃O₄ enhanced its PL and increased its stability in water. CDs have been demonstrated to enhance the PL and stability of NPs,³¹ and the hydrophilic material can be more easily absorbed in the human body for clinical application and prevent side effects.⁵⁶ To prove the above-mentioned statement, some characterizations were performed in the present study.

DLS was applied to first determine the obtained samples, which were dispersed in water, as shown in Fig. 1a. The size distribution data showed that Fe₃O₄ (I) had the biggest average particle size distribution, up to 1814 nm; this phenomena proved that the obtained Fe₃O₄ particles synthesized by co-precipitation are seemingly unstable and tend to agglomerate in water.^{3,23} Introducing CA on the magnetite (to perform Fe₃O₄@CA) drives down its average particle diameter to 1221 nm. The size lowering was due to the coating of CA's functional groups onto Fe₃O₄, preventing it to from agglomerating, thereby increasing its hydrodynamic stability and decreasing the particle size. Moreover, the nanohybrid Fe₃O₄@CDs reached the smallest average particle size (up to 198.8 nm). These phenomena showed that the abundance of CA's functional groups can be optimized to prevent Fe₃O₄ aggregation and form CDs as stable coating structures. Next, the AFM images visualise the topography of Fe₃O₄@CDs, where the height of Fe₃O₄@CDs was measured to be 10 nm to 35 nm, as shown in Fig. 1b and c. The size distribution of Fe₃O₄@CD particles was calculated using a Gaussian equation on the Origin software. As shown in Fig. 1d, the Fe₃O₄@CDs were 18.2 \pm 0.3 nm in diameter, which support the previous data





Scheme 1 Schematic route for developing nanohybrid naproxen-loaded magnetite carbon dots ($\text{Fe}_3\text{O}_4\text{@CDs-NAP}$).

confirming that $\text{Fe}_3\text{O}_4\text{@CDs}$ have a smaller size than that of bare Fe_3O_4 . These data also revealed the effectiveness of CA on covering the magnetite well and the capability of degrading the Fe_3O_4 size.⁵⁷ For supporting the AFM data, the TEM observation was further conjugated to the nanohybrid (Fig. 2). TEM also confirms that addition of CDs may reduce Fe_3O_4 size from above 25 nm (Fe_3O_4) to below 25 nm ($\text{Fe}_3\text{O}_4\text{@CDs}$), on average. This finding also reveals that the incorporation of CDs onto magnetite reduces the aggregation potency that can be further advantageous for applications. With regard to the previous report on the use of nanomaterials for endocytosis and controlled drug release process, Fe_3O_4 is generally less than 345 nm in diameter;^{58,59} the finding of the size of $\text{Fe}_3\text{O}_4\text{@CDs}$ may strengthen the potential application of the nanohybrid in biomedical fields.

The crystal structures of Fe_3O_4 , $\text{Fe}_3\text{O}_4\text{@CA}$, and $\text{Fe}_3\text{O}_4\text{@CDs}$ were then compared *via* XRD observation, where the patterns fit




Fig. 2 TEM images of Fe_3O_4 (a) and $\text{Fe}_3\text{O}_4\text{@CDs}$ (b). The bars represent 50 nm.

with JCPDS 75-0033, confirming the existence of magnetite structures on nanohybrids (shown in Fig. 3). In detail, all samples showed similar Miller indices of Fe_3O_4 on (220), (311), (222), (311), (400), (511), and (440) planes. By using the Scherrer equation, the crystal diameter of the Fe_3O_4 , $\text{CA@Fe}_3\text{O}_4$ and $\text{Fe}_3\text{O}_4\text{@CDs}$ were confirmed to be 3.79, 3.78, and 3.09 nm, respectively. These findings also support the previous results that the size of magnetite decreases once it is conjugated with CA. This makes it suitable for possible therapeutic applications because materials less than 100 nm in diameter have favourable biodistribution and clearance/accumulation behaviour in the human body.²⁵

Subsequently, absorption and emission of $\text{Fe}_3\text{O}_4\text{@CDs}$ were monitored by UV-vis and PL spectrophotometry. From both assessments, it was confirmed that the produced $\text{Fe}_3\text{O}_4\text{@CDs}$ had a maximum absorbance at 230.5 nm, indicating the $\pi \rightarrow \pi^*$ electron transition of the C=C bond in the CD core.³¹ Additionally, a shoulder peak was present at 329 nm, which demonstrates the $n \rightarrow \pi^*$ electron transition of the carbonyl group (Fig. 4a).¹ The emission spectrum of $\text{Fe}_3\text{O}_4\text{@CDs}$ at 410 nm is displayed in Fig. 4b; the spectra showed blue fluorescence with red-shifted emission and excitation wavelengths, as the excitation wavelength was increased.^{60,61} To attain significant improvement in spectrophotometer observation, we next compared the absorbance of bare magnetite, $\text{Fe}_3\text{O}_4\text{@CA}$ and the $\text{Fe}_3\text{O}_4\text{@CDs}$ (Fig. S1, ESI[†]), and the nanohybrid showed




Fig. 1 (a) Dynamic light scattering (DLS) particle diameter distribution: (i) Fe_3O_4 ; (ii) citric-acid-coated Fe_3O_4 ($\text{Fe}_3\text{O}_4\text{@CA}$); and (iii) $\text{Fe}_3\text{O}_4\text{@CDs}$. (b) 2D and (c) 3D morphology of $\text{Fe}_3\text{O}_4\text{@CDs}$. (d) Size distribution.






Fig. 3 X-ray diffraction (XRD) patterns of pure magnetite (red), Fe_3O_4 @CA composite (blue), and Fe_3O_4 @CDs (green), verified with Fe_3O_4 JCPDS database.

several absorption peaks at significantly higher emission compared to the bare magnetite and Fe_3O_4 @CA. This finding proved the attachment of CDs on the surface of magnetite with chemical binding. This interaction may happen, because CDs have shown good attraction with metal elements. Such property was even utilized for their use in metals.^{62,63} Next, the QY percentage of the resulting Fe_3O_4 @CDs reached up to 56.5%, where it was classified as a high QY among the reported metal-doped hybrid CDs, as detailed in Table 1. This finding confirms the good potency of the nanohybrid for use as a staining agent.

Functional group observation of the nanohybrid was done by FTIR to verify the surface modification of magnetite. The synthesized Fe_3O_4 , Fe_3O_4 @CA, Fe_3O_4 @CDs, and Fe_3O_4 @CDs-

NAP samples were examined at wavenumbers of 400–4000 cm^{-1} ; the resulting spectra are shown in Fig. 4c. The 561–640 cm^{-1} band present in the synthesized Fe_3O_4 spectrum is associated with the Fe–O bonding of spinel ferrite.⁶⁴ Moreover, the broad bands at 3442 and 1629 cm^{-1} indicate the presence of O–H stretching and bending that occurs during co-precipitation, respectively. The spectrum of NAP showed several bands at 1680 and 1165 cm^{-1} that correspond to C=O and the C–O–C/methoxy groups contained in NAP, respectively. The band at 1589 cm^{-1} is present in the Fe_3O_4 @CA spectrum, but not in that of Fe_3O_4 @CDs associated with a C=C aromatic group, and thus, represents the dehydrogenation of CA forming graphene oxides during furnacing.⁶⁵ Finally, the generated band at 1135 cm^{-1} in the spectrum of the synthesized Fe_3O_4 @CDs-NAP corresponds to the methoxy group of NAP, and thus, demonstrates the successful loading of NAP onto Fe_3O_4 @CDs.

The measurement of the magnetic properties of samples was carried out using a VSM at room temperature at a magnetic field intensity of 8000–8000 Oe; the resulting saturation magnetization (M_s), remanent magnetization (M_r), and coercivity (H) are shown in Fig. 5. The resulting saturation magnetization of Fe_3O_4 , Fe_3O_4 @CA and Fe_3O_4 @CDs was 80.569, 59.573, and 68.379 emu per g, respectively. The saturation magnetization of the synthesized materials was thus lower than that of Fe_3O_4 (92–100 emu per g) by a significant margin, thereby indicating that the sample was smaller than bulk Fe_3O_4 . The saturation magnetization ratio for those samples compared with bulk Fe_3O_4 was 64.75%, 87.58%, and 74.33%, respectively. If the magnetization hysteresis curve is enlarged, the coercivity obtained from Fe_3O_4 , Fe_3O_4 @CA and Fe_3O_4 @CDs was 25.462, 5.637 and 24.460 G, respectively, and the remanent magnetization was near zero: 2.679, 0.718 and 3.617 emu per g, respectively. The characteristic features of superparamagnetic include high saturation magnetization, low coercivity and remanent magnetization of zero when not influenced by an external magnetic field. The data derive an opinion that the





Fig. 4 (a) Ultraviolet (UV) spectrum and (b) PL intensity of Fe_3O_4 @CDs with varied excitation wavelength (320–420 nm). (c) Infrared (IR) spectra of NAP (black), Fe_3O_4 (red), Fe_3O_4 @CA (blue), Fe_3O_4 @CDs (green), and Fe_3O_4 @CDs-NAP (orange).



Table 1 Quantum yields (QY) of various metal carbon-based nanoparticles (NPs)

Precursor	Sample	Method	QY (%)	Ref
Citrate acid, ethanediamine	CQDs	Hydrothermal	48.32	1
Citrate acid, ethanediamine, GdCl ₃	Gd-CQDs	Hydrothermal	31.78	
Citrate acid, ethanediamine, GdCl ₃ , N-Fe ₃ O ₄	Gd-CQDs@N-Fe ₃ O ₄	Solvothermal	1.29	
Black phosphorus, poly-lysine acid, ferric ammonium citrate, polyglutamic acid	GP-PGA-Fe ₃ O ₄ -CDs@BPQDs	Hydrothermal	6.8	2
Ferric ammonium citrate and triethylenetetramine	Fe ₃ O ₄ -CDs	Hydrothermal	4.8	4
Citrate acid, FeCl ₃ , (NH ₄) ₂ Fe(SO ₄) ₂ ·6H ₂ O	Fe ₃ O ₄ @CDs	Furnace-assisted	56.5	Present study

Fig. 5 Magnetization curve of Fe₃O₄, Fe₃O₄@CA, and Fe₃O₄@CDs.

addition of CA onto magnetite will diminish the magnetic properties due to the formation of huge amorphous regions on the surface of magnetite; meanwhile, further carbonation of CA forming Fe₃O₄@CDs surprisingly enhances the magnetic properties. The emerged magnetic properties on the Fe₃O₄@CDs could also be observed easily (Fig. S2, ESI†). Basically, formation of graphene-like structures on CDs is a responsible factor in increasing the magnetic properties, where the magnetic character emerged from the edge state of the graphene-like structure of CDs, resulting in dislocated energy within the pseudo gap.^{66,67} These properties have only been demonstrated to appear for nano-sized materials and the obtained low remanent magnetization along with its coercivity value indicates that the three samples have superparamagnetic properties.^{23,58}

In order to evaluate its use for biomedical application, the stability investigation of the nano hybrid is a crucial aspect that needs to be explored. We considered to assess the stability of Fe₃O₄@CDs against different pH values and ionic strength, where these two aspects are important regarding future studies *in vivo* and clinical administration on insertion of this nano hybrid. We next use a turbidimeter for assessing any nano hybrid degradation (Fig. S3, ESI†). The data illustrated that the nano hybrid exhibited low turbidity data in the pH range of 3–10, indicating good stability under that condition. Moreover,

the Fe₃O₄@CDs nano hybrid also showed good stability while it is against high-ionic strength condition (NaCl concentration up to 3 N). The good stability of the nano hybrid at different pH values and NaCl concentrations indicates the good potency of this nanomaterial in biomedical applications (normally at pH 7.4 and NaCl concentration at 0.15 N).

Cytotoxicity evaluation

The cytotoxicity of the Fe₃O₄@CDs against HeLa cancer cells after 24 h was assessed using the CCK-8 (Fig. 6). Even at a high concentration up to 600 μg mL⁻¹, the cell viability treated with Fe₃O₄@CDs is still maintained at a high percentage over 80%, which strongly demonstrates the high biocompatibility of the obtained Fe₃O₄@CDs. It is well known that CDs exhibited excellent biocompatibility and non-toxic features.⁶⁸ In the nano hybrid design, even Fe₃O₄ and other metal ferrites claimed also have low toxic effects;^{52,53,69} CDs acting like a cover on the surface of magnetite nanoparticles would possibly prevent toxic reactions between the nanoparticles and the cellular system. Moreover, the half-maximal cytotoxic concentration (CC₅₀) of Fe₃O₄@CDs also supported this statement in proving the non-toxic property of the nano hybrid, even at a concentration as high as 17 671.5 ± 1742.6 μg mL⁻¹ (shown on Fig. 7a). This finding also reveals that the CDs play an important role, not only in emerging optical properties, but also in their ability to cover




Fig. 6 Cell viability evaluation of HeLa cells by a CCK-8 assay after 24 h of incubation with Fe₃O₄@CDs (green) and Fe₃O₄@CDs-NAP (orange) compared with the negative control. All data are expressed as mean ± SD, *n* = 5.






Fig. 7 HeLa cancer cell viability curves after 24 h incubation of (a) Fe₃O₄@CD nanohybrids and (b) inhibition of HeLa cancer cell curves after 24 h incubation of loaded Fe₃O₄@CDs-NAP nanohybrids. CC₅₀ and IC₅₀ values were plotted on the red fitted curves that resulted from dose-response mode on the Origin software. All data are expressed as mean ± SD with *n* = 3.

the magnetite nanoparticle and diminish the toxicity effect of the nanohybrid. The CC₅₀ result of nanohybrid is also comparable with the other CD-based studies that claimed non-toxic nanomaterials (Table S1, ESI[†]). Furthermore, loading naproxen on the nanohybrid drives the cell viability percentage down significantly even at its low concentrations. The inhibited concentration (IC₅₀) of Fe₃O₄@CDs-NAP was $8.42 \pm 1.09 \mu\text{g mL}^{-1}$ (see Fig. 7b). Interestingly, this IC₅₀ value was lower than that of naproxen itself ($28.20 \pm 1.09 \mu\text{g mL}^{-1}$).⁷⁰ However, it is an intriguing observation regarding the ability of an anti-inflammatory drug to inhibit cancer cells. This was considering previous reports in the literature that revealed the anticancer activity of naproxen derivatives.⁷¹ The loading of NAP on the surface of Fe₃O₄@CDs more possibly occurs by interactions between the functional groups on both naproxen and Fe₃O₄@CDs surface. Such interaction likely influenced the observed enhancement in the anticancer activity. Furthermore, the magnetic nanoparticles coated with methionine and PEG were similarly used to deliver naproxen to cancer cells (MDA-MB-231 and MCF-7) with obvious enhanced anticancer activity.⁷² Therefore, the easily synthesized Fe₃O₄@CDs showed good performance not only as non-toxic staining agents, but also in delivering naproxen well to cell target and upgrading the effectiveness of HeLa cancer cell inhibition. This finding further opens the potency on MNP utilization for developing improved cancer disease treatment.⁷³

Confocal investigation

Confocal laser scanning microscopy (CLSM) investigation was next conducted to observe the capability of Fe₃O₄@CDs in targeting HeLa cancer cells. This aspect is important to elaborate the possibility of the nanohybrid for effective naproxen delivery to the targeted cell. Moreover, the CLSM is good data to prove the potential application of Fe₃O₄@CDs acting as staining agents on the cancer cell. From Fig. S4 (ESI[†]), it is clear to that HeLa cells show green fluorescence after 1 h incubation with Fe₃O₄@CDs. By adding DAPI for particular nucleus cell staining, it confirmed the nanohybrid converge on the cytoplasm area of the cell. The nanohybrid transport and its insertion to

the cell was mediated by physical interactions, mainly hydrogen bonding and electrostatic interaction with the cell membrane, allowing the existence of the nanohybrid on the cytoplasm as the final target.⁷⁴ This CLSM result is quite clear to detecting the CDs' emission on the cell indicating role of CDs on the nanohybrid can work well.

NAP release evaluation

The releasing properties of the nanohybrid in naproxen delivery need to be improved for targeted delivery in clinical applications. The drug release profile was characterized by a dissolution test under adjusted conditions. The pH of the release medium also affected the amount of NAP released, as shown in Fig. 8. At pH = 7, 1.56% of the NAP was released after 360 min; this value decreased at pH = 9 and 4 to 1.48% and 1.33%, respectively. After 1440 min, the total released NAP at pH = 7, 9, and 4 were 1.66%, 1.47% and 1.36%, respectively. This pH-




Fig. 8 Dissolution of Fe₃O₄@CDs nanohybrids at different pH values. All data are expressed as mean ± SD, *n* = 3.






Fig. 9 Kinetic release of NAP from Fe_3O_4 @CDs at varied pH (pH 4: green; pH 7: red; pH 9: blue) and compared to the 0-order, 1st-order, Higuchi (H), and Korsmeyer–Peppas (KP) models.

dependent response was potentially due to the improved electrostatic attraction of CDs. A slightly basic medium can well dissolve NAP; remarkably, CDs contain plentiful high-power moieties (*i.e.*, hydroxyl and carboxyl functional groups) that can provide an electronegative charge. This induced the electronegative charge that can prompt high electrostatic aversion. In depth, dissolution data of Fe_3O_4 @CDs-NAP at different pH values were also compared with common drug release patterns, such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas kinetics models (Fig. 9). The obtained drug data closely followed the Korsmeyer–Peppas kinetics pattern (see on Table S2†). The model describes the releasing model of the drug from a polymeric material or any material with an organized structure;⁶⁴ this finding indicates that naproxen release is influenced by Fe_3O_4 @CDs. The graphene-like structure that existed on CDs and Fe_3O_4 crystal maybe detected as an organized structure that has effects naproxen's motion. In this kinetics model, the diffusion exponent (n) defines the influence drug release mechanism. When $n \leq 0.45$, the drug release mechanism can be described by the Fickian diffusion; $0.45 < n < 0.89$ corresponds to a non-Fickian transport mechanism, $n = 0.89$ corresponds to case II (relaxational) transport, and $n > 0.89$ corresponds to a super case II transport mechanism.^{75,76} The resulting diffusion exponent (n) at pH = 4, 7 and 9 was 0.2464037, 0.3252665 and 0.2858769, respectively, indicating that the drug release mechanism followed the Fickian diffusion.

Conclusion

Nanohybrid Fe_3O_4 coated with CDs has been successfully synthesized and characterized in the present study. The characterization results validated the structure of Fe_3O_4 as well as CDs surrounding it; it was confirmed that each component maintained its functionalities. The obtained Fe_3O_4 @CD nanohybrid gives a high QY; meanwhile, it still also maintains its magnetic properties. The CA

has been proven to stabilize magnetite, and also showed a decreased size diameter of the nanohybrid on Fe_3O_4 @CDs. The cytotoxicity experiment demonstrated that the nanohybrid was non-toxic and allowed naproxen to be delivered specifically to HeLa cells. The developed nanohybrid also demonstrated pH-dependent NAP release that followed the Korsmeyer–Peppas kinetics model. This finding on multi-tasking nanohybrid refers to an integrative way on cancer treatment clinically.

Conflicts of interest

The authors declare that no known competing financial interests or personal relationships influence the work on this paper.

Abbreviations

Magnetic nanoparticles	(MNPs)
Carbon dots	(CDs)
Quantum yield	(QY)
Magnetite	(Fe_3O_4)
Citric acid	(CA)
Naproxen	(NAP)
Computer tomography	(CT)
Magnetic resonance imaging	(MRI)
Deionised	(DI)
CA-coated Fe_3O_4	(Fe_3O_4 @CA)
Photoluminescence	(PL)
Nanohybrid Fe_3O_4 CDs	(Fe_3O_4 @CDs)
NAP-loaded Fe_3O_4 @CDs	(Fe_3O_4 @CDs-NAP)
Ultraviolet-visible spectrophotometry	(UV-vis)
Fourier-transform infrared spectroscopy	(FTIR)
Atomic force microscopy	(AFM)
Dynamic light scattering	(DLS)
X-ray diffraction	(XRD)
Enzyme-linked immunosorbent assay	(ELISA)
Vibrating-sample magnetometer	(VSM)
Cell Counting Kit-8	(CCK-8)
Dimethyl sulfoxide	(DMSO)
Sodium hydroxide	(NaOH)
Ethanol	($\text{C}_2\text{H}_5\text{OH}$)
Dulbecco's modified Eagle's medium	(DMEM)
Cytotoxic concentration	(CC50)
Inhibitory concentration	(IC50)
Rhodamine 6G	(R6G)

Acknowledgements

The authors thank to Ministry of Research, Technology, and Higher Education Republic of Indonesia under contract No. 928/UN3.15/PT/2022 and 010/E5/PG.02.00.PT/2022.

References

- 1 Y. Huang, L. Li, D. Zhang, L. Gan, P. Zhao, Y. Zhang, Q. Zhang, M. Hua and C. Jia, *Magn. Reson. Imaging*, 2020, **68**, 113–120.



- 2 M. Zhang, W. Wang, Y. Cui, N. Zhou and J. Shen, *Int. J. Nanomed.*, 2018, **13**, 2803.
- 3 J. Shan, L. Wang, H. Yu, J. Ji, W. Amer, Y. Chen, G. Jing, H. Khalid, M. Akram and N. Abbasi, *Mater. Sci. Technol.*, 2016, **32**, 602–614.
- 4 B. Li, X. Wang, Y. Guo, A. Iqbal, Y. Dong, W. Li, W. Liu, W. Qin, S. Chen and X. Zhou, *Dalton Trans.*, 2016, **45**, 5484–5491.
- 5 F. Zhu, D. Li, Q. Ding, C. Lei, L. Ren, X. Ding and X. Sun, *Biosens. Bioelectron.*, 2020, **147**, 111787.
- 6 S. M. Fotukian, A. Barati, M. Soleymani and A. M. Alizadeh, *J. Alloys Compd.*, 2020, **816**, 152548.
- 7 D. H. Kim, D. W. Kim, J. Y. Jang, N. Lee, Y.-J. Ko, S. M. Lee, H. J. Kim, K. Na and S. U. Son, *ACS Appl. Mater. Interfaces*, 2020, **12**, 37628–37636.
- 8 S. Sadighian, N. Bayat, S. Najafloo, M. Kermanian and M. Hamidi, *ChemistrySelect*, 2021, **6**, 2862–2868.
- 9 Y. Zhang, X. Li, Y. Zhang, J. Wei, W. Wang, C.-Z. Dong, Y. Xue, M. Liu and R. Pei, *New J. Chem.*, 2021, **45**, 7918–7941.
- 10 B. Maleki, H. Alinezhad, H. Atharifar, R. Tayebbe and A. V. Mofrad, *Org. Prep. Proced. Int.*, 2019, **51**, 301–309.
- 11 N. B. Dewage, A. S. Liyanage, C. U. Pittman Jr, D. Mohan and T. Mlsna, *Bioresour. Technol.*, 2018, **263**, 258–265.
- 12 E. Kim, K. Lee, Y.-M. Huh and S. Haam, *J. Mater. Chem. B*, 2013, **1**, 729–739.
- 13 T. Kang, F. Li, S. Baik, W. Shao, D. Ling and T. Hyeon, *Biomaterials*, 2017, **136**, 98–114.
- 14 A. Jesus, J. Jesus, R. Lima, K. Moura, J. Almeida, J. Duque and C. Meneses, *Ceram. Int.*, 2020, **46**, 11149–11153.
- 15 F. Zhan, R. Wang, J. Yin, Z. Han, L. Zhang, T. Jiao, J. Zhou, L. Zhang and Q. Peng, *RSC Adv.*, 2019, **9**, 878–883.
- 16 C. Li, Y. Fu, Z. Wu, J. Xia and X. Wang, *Nanoscale*, 2019, **11**, 12997–13006.
- 17 D. Liu, J. Lai, R. Wang, L. Ye and Y. Tian, *ACS Biomater. Sci. Eng.*, 2019, **5**, 6196–6206.
- 18 P. Hu, T. Chang, W.-J. Chen, J. Deng, S.-L. Li, Y.-G. Zuo, L. Kang, F. Yang, M. Hostetter and A. A. Volinsky, *J. Alloys Compd.*, 2019, **773**, 605–611.
- 19 H. Veisi, M. Ghorbani and S. Hemmati, *Mater. Sci. Eng., C*, 2019, **98**, 584–593.
- 20 M. O. Besenhard, A. P. LaGrow, S. Famiani, M. Pucciarelli, P. Lettieri, N. T. K. Thanh and A. Gavriilidis, *React. Chem. Eng.*, 2020, **5**, 1474–1483.
- 21 H. Sadegh, H. Helmi, A. S. Hamdy, A. Masjedi, M. J. H. Dastjerdi and R. Shahryari-ghoshekandi, *Chem. Adv. Mater.*, 2016, **1**, 1–12.
- 22 J.-F. Lin, C.-C. Tsai and M.-Z. Lee, *J. Magn. Magn. Mater.*, 2014, **372**, 147–158.
- 23 X. Liu, C. Chen, Y. Zhao and B. Jia, *J. Nanomater.*, 2013, **34**, 1–7.
- 24 W. Ling, M. Wang, C. Xiong, D. Xie, Q. Chen, X. Chu, X. Qiu, Y. Li and X. Xiao, *J. Mater. Res.*, 2019, **34**, 1828–1844.
- 25 J. A. Barreto, W. O'Malley, M. Kubeil, B. Graham, H. Stephan and L. Spiccia, *Adv. Mater.*, 2011, **23**, 18–40.
- 26 Z. Xie, F. Wang and C. y. Liu, *Adv. Mater.*, 2012, **24**, 1716–1721.
- 27 J. Nam, N. Won, J. Bang, H. Jin, J. Park, S. Jung, S. Jung, Y. Park and S. Kim, *Adv. Drug Delivery Rev.*, 2013, **65**, 622–648.
- 28 S. F. A. Sugito, F. Firdaus, Y. Aung, S. C. W. Sakti, H.-T. Chiu and M. Z. Fahmi, *J. Mater. Res.*, 2022, 1–11.
- 29 Z. Zhang, G. Yi, P. Li, X. Zhang, H. Fan, Y. Zhang, X. Wang and C. Zhang, *Nanoscale*, 2020, **12**, 13899–13906.
- 30 D. Xu, F. Lei, H. Chen, L. Yin, Y. Shi and J. Xie, *RSC Adv.*, 2019, **9**, 8290–8299.
- 31 A. Wibrianto, S. Q. Khairunisa, S. C. Sakti, Y. L. Ni'mah, B. Purwanto and M. Z. Fahmi, *RSC Adv.*, 2021, **11**, 1098–1108.
- 32 K. Hola, Y. Zhang, Y. Wang, E. P. Giannelis, R. Zboril and A. L. Rogach, *Nano Today*, 2014, **9**, 590–603.
- 33 S. Kang, Y. K. Jeong, J. H. Ryu, Y. Son, W. R. Kim, B. Lee, K. H. Jung and K. M. Kim, *Appl. Surf. Sci.*, 2020, **506**, 144998.
- 34 M. Ali, R. Riaz, A. S. Anjum, K. C. Sun, H. Li, S. Ahn, S. H. Jeong and M. J. Ko, *J. Colloid Interface Sci.*, 2021, **586**, 349–361.
- 35 M. Z. Fahmi, J. K. Chen, C. C. Huang, Y. C. Ling and J.-Y. Chang, *J. Mater. Chem. B*, 2015, **3**, 5532–5543.
- 36 M. Ashrafzadeh, R. Mohammadinejad, S. K. Kailasa, Z. Ahmadi, E. G. Afshar and A. Pardakhty, *Adv. Colloid Interface Sci.*, 2020, **278**, 102123.
- 37 D. Dey, T. Bhattacharya, B. Majumdar, S. Mandani, B. Sharma and T. K. Sarma, *Dalton Trans.*, 2013, **42**, 13821–13825.
- 38 M. Zheng, Z. Xie, D. Qu, D. Li, P. Du, X. Jing and Z. Sun, *ACS Appl. Mater. Interfaces*, 2013, **5**, 13242–13247.
- 39 Y. Lin, B. Yao, T. Huang, S. Zhang, X. Cao and W. Weng, *Microchim. Acta*, 2016, **183**, 2221–2227.
- 40 S. K. Kailasa and J. R. Koduru, *Trends Environ. Anal. Chem.*, 2022, **33**, e00153.
- 41 M. Z. Fahmi, K.-L. Ou, J.-K. Chen, M.-H. Ho, S.-H. Tzing and J.-Y. Chang, *RSC Adv.*, 2014, **4**, 32762–32772.
- 42 S. P. Singh, *J. Biomed. Nanotechnol.*, 2011, **7**, 95–97.
- 43 X. Ren, H. Chen, V. Yang and D. Sun, *Front. Chem. Sci. Eng.*, 2014, **8**, 253–264.
- 44 J. Xie, G. Liu, H. S. Eden, H. Ai and X. Chen, *Acc. Chem. Res.*, 2011, **44**, 883–892.
- 45 N. Kaur, P. Tiwari, Z. Abbas and S. M. Mobin, *J. Mater. Chem. B*, 2022, **10**, 5251–5262.
- 46 J. Cheng, R. Xia, H. Li, Z. Chen, X. Zhou, X. Ren, H. Dong, R. Lin and J. Zhou, *ACS Sustainable Chem. Eng.*, 2022, **10**, 3935–3950.
- 47 X. Lin, Y. Mei, C. He, Y. Luo, M. Yang, Y. Kuang, X. Ma, H. Zhang and Q. Huang, *Front. Chem.*, 2021, **9**, 1–8.
- 48 Y. Hu, P. Wang, C. E. Bunker, L. R. Teisl, M. Reibold, S. Yan, H. Qian, D. He and Y.-P. Sun, *RSC Adv.*, 2017, **7**, 41304–41310.
- 49 W. Purnamasari, T. A. Budiastanti, A. Aminatun, U. Rahmah, S. Sumarsih, J.-Y. Chang and M. Z. Fahmi, *RSC Adv.*, 2022, **12**, 8019–8029.
- 50 S. Javanbakht, N. Nazari, R. Rakhshaei and H. Namazi, *Carbohydr. Polym.*, 2018, **195**, 453–459.
- 51 H. El Ghandoor, H. M. Zidan, M. M. H. Khalil and M. I. M. Ismail, *Int. J. Electrochem. Sci.*, 2012, **7**, 5734–5745.




- 52 M. Z. Fahmi, J.-K. Chen, C.-C. Huang, Y.-C. Ling and J.-Y. Chang, *J. Mater. Chem. B*, 2015, **3**, 5532–5543.
- 53 T. P. Armedya, M. F. Dzikri, S. C. W. Sakti, A. Abdulloh, Y. Raharjo, S. Wafiroh and M. Z. Fahmi, *J. Bionanosci.*, 2019, **9**, 274–284.
- 54 K. Lawson-wood, S. Upstone and K. Evans, in *Fluorescence Spectroscopy*, PerkinElmer Inc., Seer Green, UK, 2018.
- 55 M. A. Dheyab, A. A. Aziz, M. S. Jameel, O. A. Noqta, P. M. Khaniabadi and B. Mehrdel, *Sci. Rep.*, 2020, **10**, 1–8.
- 56 R. Jin, B. Lin, D. Li and H. Ai, *Curr. Opin. Pharmacol.*, 2014, **18**, 18–27.
- 57 C. Li, Z. Li, X. Ye, X. Yang, G. Zhang and Z. Li, *Chem. Eng. J.*, 2018, **334**, 1614–1620.
- 58 Y. Tu, F. Peng, P. B. White and D. A. Wilson, *Angew. Chem., Int. Ed.*, 2017, **56**, 7620–7624.
- 59 W. J. Zhang, C. Y. Hong and C. Y. Pan, *Macromol. Rapid Commun.*, 2019, **40**, 1800279.
- 60 Y. Wen, M. Xu, X. Liu, X. Jin, J. Kang, D. Xu, H. Sang, P. Gao, X. Chen and L. Zhao, *Colloids Surf., B*, 2019, **173**, 842–850.
- 61 N. Tejwan, A. K. Saini, A. Sharma, T. A. Singh, N. Kumar and J. Das, *J. Controlled Release*, 2021, **330**, 132–150.
- 62 N. Murugan and A. K. Sundramoorthy, *New J. Chem.*, 2018, **42**, 13297–13307.
- 63 N. Murugan, M. Prakash, M. Jayakumar, A. Sundaramurthy and A. K. Sundramoorthy, *Appl. Surf. Sci.*, 2019, **476**, 468–480.
- 64 M. Z. Fahmi, R. A. Prasetya, M. F. Dzikri, S. C. W. Sakti and B. Yulianto, *Mater. Chem. Phys.*, 2020, **250**, 123055.
- 65 G. Supriyanto, N. K. Rukman, A. K. Nisa, M. Jannatin, B. Piere, A. Abdullah, M. Z. Fahmi and H. S. Kusuma, *BioResources*, 2018, **13**, 4832–4840.
- 66 T. Espinosa-Ortega, I. Luk'yanchuk and Y. Rubo, *Phys. Rev. B: Condens. Matter Mater. Phys.*, 2013, **87**, 205434.
- 67 F. Zhang, F.-G. Zhang, S.-Q. Liu, J. Meng, H.-L. Miao and W. Jiang, *Chin. J. Phys.*, 2020, **66**, 390–400.
- 68 M. Havrdova, K. Hola, J. Skopalik, K. Tomankova, M. Petr, K. Cepe, K. Polakova, J. Tucek, A. B. Bourlinos and R. Zboril, *Carbon*, 2016, **99**, 238–248.
- 69 M. Z. Fahmi and J.-Y. Chang, *RSC Adv.*, 2014, **4**, 56713–56721.
- 70 E. ÇETİN, Y. D. ARACAGÖK, H. GÖKER, M. A. ONUR and N. CİHANGİR, *Hacettepe Journal of Biology and Chemistry*, 2021, **49**, 25–36.
- 71 M. M. Alam, S. Nazreen, A. S. Almalki, A. A. Elhenawy, N. I. Alsenani, S. E. I. Elbehairi, A. M. Malebari, M. Y. Alfaifi, M. A. Alsharif and S. Y. Alfaifi, *Pharmaceuticals*, 2021, **14**, 870.
- 72 F. E. Yeganeh, A. E. Yeganeh, M. Yousefi, B. Farasati Far, I. Akbarzadeh, D. O. Bokov, K. Raahemifar and M. Soltani, *Cancers*, 2022, **14**, 1797.
- 73 M. Z. Fahmi, W. Sukmayani, S. Q. Khairunisa, A. M. Witaningrum, D. W. Indriati, M. Q. Y. Matondang, J. Y. Chang, T. Kotaki and M. Kameoka, *RSC Adv.*, 2016, **6**, 92996–93002.
- 74 B. Li, X. Wang, Y. Guo, A. Iqbal, Y. Dong, W. Li, W. Liu, W. Qin, S. Chen, X. Zhou and Y. Yang, *Dalton Trans.*, 2016, **45**, 5484–5491.
- 75 G. Yadav, M. Bansal, N. Thakur, S. Khare and P. Khare, *J. Sci. Res.*, 2013, **16**, 782–795.
- 76 M. Z. Fahmi, N. F. Sholihah, A. Wibrianto, S. C. Sakti, F. Firdaus and J.-y. Chang, *Mater. Chem. Phys.*, 2021, **267**, 124596.



(/).



Journals, books & databases



RSC Advances

At the heart of open access for the global chemistry community

Read this journal
<http://pubs.rsc.org/en/journals/journalissues/ra>

Submit your article
<https://mc.manuscriptcentral.com/rscadv>

Supporting our community through Covid-19

We know that this is a very challenging time for everyone, for many different reasons. If any aspect of the publishing process is worrying you – for example you think you may struggle to meet a pre-determined deadline – please let us know, and we will work out an answer together.

Setting up remote access to RSC content

You can find details about how to access information remotely in this [step-by-step guide](/covid-19-response/publishing-remote-access/). The guide will also help if for any reason you have difficulty accessing the content you want.

RSC Advances publishes advances in chemistry, and in topics of interest to the chemistry community.

Thoughts from our Editor-in-chief



"Scientific publishing is entering an exciting period when high ethical standards, visibility and impact are all important to authors. I'm honoured to be chairing the board of *RSC Advances* which has already pioneered an open access publishing model for the benefit of authors and readers."

Russell J Cox, Editor-in-chief.

As the largest gold open access journal dedicated to the chemical sciences, we are here for everyone who wants to publish quality chemistry research and share it with the world.

We are here for everyone who needs access to work in every area of the chemical sciences and related disciplines.

And as part of the Royal Society of Chemistry, we are at the heart of open, international research dissemination for the chemistry community.

Great science matters. We make sure the world knows it.



Impact factor: 3.119*

Indexed in Scopus, Web of Science and DOAJ



Breadth

We publish work in all areas of chemistry and reach a global readership



Affordability

Low APCs, discounts and waivers make publishing open access achievable and sustainable



Quality

Research to advance the chemical sciences undergoes rigorous peer review for a trusted, society-run journal



Community

Led by active researchers, we publish quality work from scientists at every career stage, and from all countries

RSC Advances in numbers

An impact factor above **3**

Submissions from **100+** countries in 2020

An average of **30** days from submission to first decision

An average acceptance rate of **46%**

Associate editors in **25+** countries

20,000+ articles free to access and growing

RSC Advances: why publish with us?



Scope

RSC Advances papers should provide an insight that advances the chemistry field. Papers that contain little or no chemistry and are not considered to be of interest or relevance to the chemistry community are not within the scope of the journal.

The criteria for publication are that the work must be high quality, well conducted and advance the development of the field. Articles submitted to the journal are evaluated by our international team of associate editors and reviewers for the overall quality and accuracy of the science presented.

Download our [full list of subject categories](https://globalassets/05-journals-books-databases/our-journals/rsc-advances/full-list-of-subject-categories-for-rsc-advances.pdf) to see the range of topics we publish in *RSC Advances*.

Please ensure you have considered the following points before submitting your manuscript.

- Does the work present a significant advance over the existing literature? **Please supply a covering letter with your submission to demonstrate how the work is advancing the field over the existing literature.**
- Have you provided sufficient evidence/data to support your conclusions?
- Have you provided adequate characterisation data for your materials/compounds? (Please check the supporting information section to ensure that the necessary requirements have been met and copies of relevant spectra have been provided where necessary.)
- Are the results discussed in the context of the literature?
- Are the references relevant and do they appropriately reflect the existing literature?

Article processing charges and licensing

Following our peer review process, if the article is accepted, the article processing charges below will be applied to your article. There are no submission charges for *RSC Advances*.

	Article processing charge
Full price	£750 (+local taxes if applicable)*
Corresponding authors from India, Indonesia and Philippines	£500 (+local taxes if applicable)
Corresponding authors from Research4Life Group A & Group B	Full APC waiver

*15% RSC member and [R&P Institution](https://journals-books-databases/open-access/read-and-publish/community/) discount available. Applicable to full price only.

Discounts and waivers are also available on an individual basis. Find out more about applying for a [waiver](https://journals-books-databases/open-access/gold-open-access/).

Corresponding authors who pay an APC and are not already members of the Royal Society of Chemistry are entitled to one year's Affiliate membership as part of their APC. Find out more about our [member benefits](https://membership-and-community/join/#benefits).

As part of the submission process, authors will be asked to agree to the *RSC Advances* open access terms & conditions.

We offer *RSC Advances* authors a choice of two Creative Commons licences, CC-BY or CC-BY-NC. Publication under these licenses means that authors retain copyright of their article, but allows users to read, download, copy, distribute, print, search, or link to the full texts of articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. Read our [open access statement](https://journals-books-databases/open-access/open-access-info/#hide1) for further information.

All published articles are deposited with LOCKSS, CLOCKSS, Portico and the British Library for archiving.



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_cox\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_cox\)](#)
Russell Cox [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_cox\)](#)

Editor-in-chief: *Leibniz Universität Hannover, Germany*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_batteas\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_batteas\)](#)

James Batteas [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_batteas\)](#)

Editorial Board Member: *Texas A&M University, USA*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_faulds\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_faulds\)](#)

Karen Faulds [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_faulds\)](#)

Editorial Board Member: *University of Strathclyde, UK*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_jun\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_jun\)](#)

Young-Shin Jun [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_jun\)](#)
Editorial Board Member: *Washington University in St Louis*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_maji\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_maji\)](#)

Tapas Kumar Maji [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_maji\)](#)
Editorial Board Member: *INCASB, India*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_Piedade\)](#)
[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_Piedade\)](#)

Manuel Minas da Piedade [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_Piedade\)](#)

Washington University in St. Louis,
USA



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_nakagaki\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_nakagaki\)](#)

Shirley Nakagaki [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_nakagaki\)](#)

Editorial Board

Member: *Universidade Federal do Paraná, Brazil*

UNICAMP, Brazil



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_pastore\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_pastore\)](#)

Heloise Oliveira Pastore [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_pastore\)](#)

Editorial Board Member:

UNICAMP, Brazil

Editorial Board Member:
University of Lisbon, Portugal



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_shibata\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_shibata\)](#)

Norio Shibata [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_shibata\)](#)

Editorial Board Member: *Nagoya Institute of Technology, Japan*



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_turner\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_turner\)](#)

Charlotta Turner [\(/journals-books-databases/about-journals/rsc-](#)



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_wetmore\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_wetmore\)](#)

Stacey Wetmore [\(/journals-books-databases/about-journals/rsc-](#)



[\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_zheng\)](#) [\(/journals-books-databases/about-journals/rsc-advances/editorial-board-members/#ra_zheng\)](#)

Qingdong Zheng [\(/journals-books-databases/about-journals/rsc-](#)

[Read more about journal members](#)

[advances/editorial-board-](#)

[members/#ra_turner\)](#)

Editorial Board Member: *Lund University, Sweden*

[Read more about journal members](#)

[advances/editorial-board-](#)

[members/#ra_wetmore\)](#)

Editorial Board Member: *University of Lethbridge, Canada*

[Read more about journal members](#)

[advances/editorial-board-](#)

[members/#ra_zheng\)](#)

Editorial Board Member: *Chinese Academy of Sciences, China*

Emerging Investigators series

We are delighted to announce the start of an Emerging Investigators series! This series will showcase some of the best research from scientists in the early stages of their independent careers. The series will be guest edited by Professor James Batteas (Texas A&M University), and articles in the series will be accepted and published throughout the year. In addition, an Editorial article featuring recent researchers in the issue will be published annually.

[Read more about this series](#) +

Outstanding Student Paper Awards

We are delighted to announce *RSC Advances* Outstanding Student Paper Awards in 2021. These awards recognise outstanding work published in the journal, for which a substantial component of the research was conducted by a student. Winning papers will be selected by the Editorial Board and Associate Editors in 2022. Winning students receive a framed certificate and will be invited by *RSC Advances* to give a virtual talk about their research to an international audience.

[Read more about these awards](#) +

Article types

RSC Advances publishes:

- Full papers
- Reviews
- Comments


[Learn more](#)

Replay


RSC Advances

COUNTRY

United Kingdom

 Universities and research institutions in United Kingdom**SUBJECT AREA AND CATEGORY**Chemical Engineering
Chemical Engineering (miscellaneous)Chemistry
Chemistry (miscellaneous)**PUBLISHER**

Royal Society of Chemistry

H-INDEX**128****PUBLICATION TYPE**

Journals

ISSN

20462069

COVERAGE

2011-2020

INFORMATION
[Homepage](#)
[How to publish in this journal](#)
[Contact](#)

Ad closed by Google

SCOPE

RSC Advances papers should provide an insight that advances the chemistry field. Papers that contain little or no chemistry and are not considered to be of interest or relevance to the chemistry community are not within the scope of the journal. The criteria for publication are that the work must be high quality, well conducted and advance the development of the field. Articles submitted to the journal are evaluated by our international team of associate editors and reviewers for the overall quality and accuracy of the science presented.

 Join the conversation about this journal

Quartiles

FIND SIMILAR JOURNALS

options

Journal

Semin Respir Crit Care Med focuses on new diagnostic and therapeutic procedures, and more

thieme.com

OPEN

1 ACS Omega
USA

88%

similarity

2 Frontiers in Chemistry
CHE

81%

similarity

3 Chemical Research in Chinese Universities
CHE

77%

similarity

4 Progress in Chemistry
CHN








77%

similarity

5 Materials Today Chemistry
GBR

77%

similarity



RSC Advances

Q1 Chemical Engineering (miscellaneous) best quartile

SJR 2019 0.74

powered by scimagojr.com

Show this widget in your own website

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com">
```

Acknowledgement of your Submission to RSC Advances - RA-ART-09-2022-005673

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Thu, Sep 8, 2022 at 7:29 PM

Reply-To: advances@rsc.orgTo: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.comCc: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com, putriindrawasih@gmail.com, M11006808@mail.ntust.edu.tw, musbahu.adam.ahmad-2020@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, jychang@mail.ntust.edu.tw

08-Sep-2022

Dear Mr Fahmi:

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-09-2022-005673

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>, Machmudah, Nurlailiatul - No ORCID iD Available, Indrawasih, Putri - No ORCID iD Available, Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Ahmad, Musbahu - <https://orcid.org/0000-0003-2875-9572>, Sakti, Satya Candara - No ORCID iD Available, Chang, Jia-Yaw - No ORCID iD Available

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

The Royal Society of Chemistry is a member of CrossCheck. Your submission may be compared against the CrossCheck database using the iThenticate plagiarism detection software. For further information, please see here: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#crosscheck>

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,
RSC Advances Editorial Office
advances@rsc.org

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Acknowledgement of your revised manuscript submission to RSC Advances - RA-ART-09-2022-005673.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>

Mon, Oct 24, 2022 at 5:09 PM

Reply-To: advances@rsc.org

To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Cc: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com, nurlailiatul.m-2014@fst.unair.ac.id, putriindrawasih@gmail.com, aswandi.wibrianto-2016@fst.unair.ac.id, M11006808@mail.ntust.edu.tw, musbahu.adam.ahmad-2020@fst.unair.ac.id, satya.sakti@fst.unair.ac.id, jychang@mail.ntust.edu.tw

24-Oct-2022

Dear Mr Fahmi:

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells
AUTHORS: Fahmi, Mochamad Zakki; Machmudah, Nurlailiatul; Indrawasih, Putri; Wibrianto, Aswandi; Ahmad, Musbahu; Sakti, Satya Candara; Chang, Jia-Yaw

Thank you for your revised submission to RSC Advances, published by the Royal Society of Chemistry. This is an automatic acknowledgement that you have uploaded your files to our online submission system. Your manuscript ID is: RA-ART-09-2022-005673.R1

Your manuscript will be passed to an editor for initial assessment as soon as possible. If there are any problems with your submission we will contact you.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

Please indicate the above manuscript ID when you contact us about this submission.

If there have been any changes to the list of authors during this revision, please inform the Editorial Office of the reason for the change. All authors must confirm they are happy with the authorship change by emailing advances@rsc.org.

Do you have an ORCID iD? ORCID (Open Researcher and Contributor iD) is a unique researcher identifier that allows you to link your research output and other professional activities in a single record. We therefore encourage each researcher to sign up for their own ORCID account. Please edit your user account to link your ORCID iD or create a new one, ensuring that you have not linked your account to another researcher's ORCID iD. Please note that we are unable to do this on your behalf. If your article is accepted, you may choose to have your ORCID record updated automatically with details of the publication.

We already have the following information for authors of this manuscript: Fahmi, Mochamad Zakki - <https://orcid.org/0000-0001-5430-9992>, Machmudah, Nurlailiatul - No ORCID iD Available, Indrawasih, Putri - No ORCID iD Available, Wibrianto, Aswandi - <https://orcid.org/0000-0002-7746-7405>, Ahmad, Musbahu - <https://orcid.org/0000-0003-2875-9572>, Sakti, Satya Candara - No ORCID iD Available, Chang, Jia-Yaw - No ORCID iD Available

If this is not how you want your name to appear on an Accepted Manuscript, please amend your ScholarOne account.

This journal has a policy of sharing reviewer reports. Please note that the Editor's decision and copies of the reports will be shared with all reviewers who provide a recommendation on your manuscript.

Please contact us if we can be of any assistance.

Yours sincerely,
RSC Advances Editorial Office
advances@rsc.org

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society

of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Decision on submission to RSC Advances - RA-ART-09-2022-005673

1 message

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Sat, Oct 15, 2022 at 12:14 PM

15-Oct-2022

Dear Mr Fahmi:

Manuscript ID: RA-ART-09-2022-005673

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for your submission to RSC Advances, published by the Royal Society of Chemistry. I sent your manuscript to reviewers and I have now received their reports which are copied below.

I have carefully evaluated your manuscript and the reviewers' reports, and the reports indicate that major revisions are necessary.

Please submit a revised manuscript which addresses all of the reviewers' comments. Further peer review of your revised manuscript may be needed. When you submit your revised manuscript please include a point by point response to the reviewers' comments and highlight the changes you have made. Full details of the files you need to submit are listed at the end of this email.

Please submit your revised manuscript as soon as possible using this link:

*** PLEASE NOTE: This is a two-step process. After clicking on the link, you will be directed to a webpage to confirm. ***

https://mc.manuscriptcentral.com/rscadv?URL_MASK=c9973cd28d06411b8c125c610806de1c

(This link goes straight to your account, without the need to log on to the system. For your account security you should not share this link with others.)

Alternatively, you can log in to your account (<https://mc.manuscriptcentral.com/rscadv>) where you will need your case-sensitive user ID and password details.

You should submit your revised manuscript as soon as possible; please note you will receive a series of automatic reminders. If your revisions will take a significant length of time, please contact me.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>

RSC Advances strongly encourages authors of research articles to include an 'Author contributions' section in their manuscript, for publication in the final article. This should appear immediately above the 'Conflict of interest' and 'Acknowledgement' sections. I strongly recommend you use CRediT (the Contributor Roles Taxonomy, <https://credit.niso.org/>) for standardised contribution descriptions. All authors should have agreed to their individual contributions ahead of submission and these should accurately reflect contributions to the work. Please refer to our general author guidelines <https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/authors-information/responsibilities/> for more information.

The Royal Society of Chemistry requires the submitting author to provide their ORCID iD when they submit a revised manuscript. This is quick and easy to do as part of the revised manuscript submission process. We will publish this information with the article, and you may choose to have your ORCID record updated automatically with details of the publication.

Please also encourage your co-authors to sign up for their own ORCID account and associate it with their account on our manuscript submission system. Please note that we are unable to do this on behalf of your co-authors. For further information see: <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/processes-policies/#attribution-id>.

I look forward to receiving your revised manuscript.

Yours sincerely,
Prof Andrea Pucci
Associate Editor, RSC Advances

REVIEWER REPORT(S):
Referee: 1

Recommendation: Major revisions

Comments:

This work reports the naproxen release study upon carbon dots coated magnetite nanohybrid as versatile theranostic of Hela cancer cells. The study is significant. However, some results of this assay are not and should be improved. A revision is required before the manuscript can be accepted.

1. What is the mechanism of forming Fe₃O₄@CDs? The authors should describe the mechanism in detail in the manuscript.
2. The authors can provide the cellular image of Fe₃O₄@CDs in Hela cancer cells.
3. At present, Fe₃O₄@CDs have been applied in many fields, and the author should introduce more about the application of carbon dots in the Introduction. Some articles can be cited in the manuscript, such as: Journal of Materials Chemistry B, 2022, 10, 5251-5262. Frontiers in bioengineering and biotechnology, 2020, 8: 614906. ACS Sustainable Chem. Eng. 2022, 10, 12, 3935-3950. Frontiers in chemistry, 2021, 9, 769648. Applied Organometallic Chemistry, 2021, 35(11): e6387. Food Chemistry, 2022, 373: 131415. Dalton Trans., 2016, 45, 5484-5491. RSC advances, 2016, 6(85): 82294-82297. New J. Chem., 2020, 44, 6635-6642. RSC Adv., 2018, 8, 8528-8536. RSC Adv., 2017, 7, 41304-41310, and so on.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: No

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

Referee: 2

Recommendation: Major revisions

Comments:

1. TEM, UV and PL spectra of Fe₃O₄@CA should be studied in this work.
2. Fe₃O₄@CDs or CDs@Fe₃O₄? The author should be unified and proved in the manuscript.
3. HRTEM and Mapping of Materials should be studied in this work.
4. Fe₃O₄@CDs have been reported in many articles. Please refer to the latest references.
5. Cellular image of Fe₃O₄@CDs in cells should be provide in the manuscript.
6. Synthesis mechanism of materials must be provide in the manuscript.

Additional Questions:

Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds>: No

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: No

Are the number of tables and figures in the manuscript appropriate and clear?: No

FILES TO PROVIDE WITH YOUR REVISED MANUSCRIPT:

IMPORTANT: Your original files are available to you when you upload your revised manuscript. Please delete any redundant files before completing the submission. Please carefully check the spelling and format of all author names, affiliations and funding

information. If your paper is accepted for publication, it is important this information is accurate to ensure your article is correctly indexed, which may affect citations and future funding evaluation. Please note that if you have selected Accepted Manuscript publication, the author list will appear as provided in the ScholarOne submission details until your Advance Article is published and this information is updated from your article.

- A point-by-point response to the comments made by the reviewer(s)
- Your revised manuscript with any changes clearly marked (.doc(x) or.pdf file)
- Your revised manuscript as a .doc(x) file including figures, without highlighting, track changes, etc. (If providing in TeX format instead, please also provide a final PDF version including figures). Please note that we cannot proceed with publication using a .pdf file only.

High quality images

EITHER
embedded in a doc(x) file
OR
as separate numbered Figures, Schemes or Charts in .tif, .eps or .pdf format, with a resolution of 600 dpi or greater.

AND

- A table of contents entry: graphic maximum size 8 cm x 4 cm and 1-2 sentence(s) of editable text, with a maximum of 250 characters (including spaces), highlighting the key findings of the work. It is recommended authors make use of the full space available for the graphic. See our Author Guidelines for more details: <https://www.rsc.org/journals-books-databases/author-and-reviewer-hub/>
- Your revised Electronic Supplementary Information (if any)
- Your revised CheckCIF reports (if any). Please ensure that any revised cif files have been deposited with the Cambridge Crystallographic Data Centre (CCDC) via <https://deposit.ccdc.cam.ac.uk/> before you submit your revised manuscript.

For Review-type articles only:

- A photograph and biography of yourself and your co-authors. Separate photographs of each author may be supplied or if you prefer, a group photograph, saved as a .tif, .pdf or .jpeg file. The resolution of the photographs should be 600 dpi or higher. The dimensions of the photograph in the printed journal will be 4 cm wide x 5 cm high (individual photograph) or 8.3 cm wide x 5 cm high (group photograph). Individual photographs should be accompanied by a maximum of 100 words; a group photograph by a maximum of 200 words. There can be a maximum of 6 individual biographies per article.
- Copies of permissions required from other publishers to reproduce figures. Please ensure that necessary permissions are acknowledged in the figure captions in accordance with the publishers' instruction. Information on how to obtain permissions and rights that we require are given on our website at <https://www.rsc.org/journals-books-databases/journal-authors-reviewers/licences-copyright-permissions/>

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org

Decision on submission to RSC Advances - RA-ART-09-2022-005673.R1

1 message

RSC Advances <onbehalf@manuscriptcentral.com>
Reply-To: advances@rsc.org
To: m.zakki.fahmi@fst.unair.ac.id, zakkifahmi@gmail.com

Thu, Oct 27, 2022 at 9:17 PM

27-Oct-2022

Dear Mr Fahmi:

Manuscript ID: RA-ART-09-2022-005673.R1

TITLE: Naproxen Release Study upon Carbon dots coated Magnetite Nanohybrid as Versatile Theranostic of HeLa Cancer Cells

Thank you for submitting your revised manuscript to RSC Advances. I am pleased to accept your manuscript for publication in its current form. I have copied any final comments from the reviewer(s) below.

You will shortly receive a separate email from us requesting you to submit a licence to publish for your article, so that we can proceed with the preparation and publication of your manuscript. We will email you information on how to access your RSC Advances article proofs when they are ready.

All RSC Advances articles are published under an open access model, and the appropriate article processing charge (APC) will apply. Details of the APC and discounted rates can be found at <https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#charges-RSC-Advances>.

How can we improve our open access publishing service for you?

Share your OA feedback in a short telephone interview in English or Mandarin to help us improve our open access publishing processes and receive a £25 Amazon voucher (or local equivalent) for your time. Find out more here: <https://www.smartsurvey.co.uk/s/OpenAccess>.

We are offering all corresponding authors who are not already members of the Royal Society of Chemistry one year's Affiliate membership as part of their APC. If you would like to find out more please email membership@rsc.org, including the promo code OA100 in your message. Learn all about our member benefits at <https://www.rsc.org/membership-and-community/join/#benefit>.

Promote your research, accelerate its impact – find out more about our article promotion services here: <https://rsc.li/promoteyourresearch>.

If you would like us to promote your article on our Twitter account @RSCAdvances please fill out this form: <https://form.jotform.com/212705294847058>. Alternatively, if you would like your article to be considered for further promotion via our WeChat channels then please do let us know.

By publishing your article in RSC Advances, you are supporting the Royal Society of Chemistry to help the chemical science community make the world a better place.

With best wishes,

Prof Andrea Pucci
Associate Editor, RSC Advances

REVIEWER REPORT(S):
Referee: 1

Recommendation: Accept

Comments:
I agree to accept this manuscript for publication on the RSC.

Additional Questions:
Does the work significantly advance the understanding or development in this field?: Yes

Is this work of relevance to the chemistry community?: Yes

Are the conclusions of the work convincing and sufficiently supported by experimental evidence?: Yes

Does the data provided fulfil the journal's data requirements?

See Journal specific guidelines: https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/#Characterisation-of-new-compounds: Yes

Is the experimental section sufficiently detailed to allow others to reproduce the work?: Yes

Are the reported claims adequately discussed in the context of the literature?: Yes

Are the number of tables and figures in the manuscript appropriate and clear?: Yes

If you need to contact the journal, please use the email address advances@rsc.org

DISCLAIMER:

This communication is from The Royal Society of Chemistry, a company incorporated in England by Royal Charter (registered number RC000524) and a charity registered in England and Wales (charity number 207890). Registered office: Burlington House, Piccadilly, London W1J 0BA. Telephone: +44 (0) 20 7437 8656.

The content of this communication (including any attachments) is confidential, and may be privileged or contain copyright material. It may not be relied upon or disclosed to any person other than the intended recipient(s) without the consent of The Royal Society of Chemistry. If you are not the intended recipient(s), please (1) notify us immediately by replying to this email, (2) delete all copies from your system, and (3) note that disclosure, distribution, copying or use of this communication is strictly prohibited.

Any advice given by The Royal Society of Chemistry has been carefully formulated but is based on the information available to it. The Royal Society of Chemistry cannot be held responsible for accuracy or completeness of this communication or any attachment. Any views or opinions presented in this email are solely those of the author and do not represent those of The Royal Society of Chemistry. The views expressed in this communication are personal to the sender and unless specifically stated, this e-mail does not constitute any part of an offer or contract. The Royal Society of Chemistry shall not be liable for any resulting damage or loss as a result of the use of this email and/or attachments, or for the consequences of any actions taken on the basis of the information provided. The Royal Society of Chemistry does not warrant that its emails or attachments are Virus-free; The Royal Society of Chemistry has taken reasonable precautions to ensure that no viruses are contained in this email, but does not accept any responsibility once this email has been transmitted. Please rely on your own screening of electronic communication.

More information on The Royal Society of Chemistry can be found on our website: www.rsc.org